Liquid biopsies and cancer omics
Open Access
- 26 November 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cell Death Discovery
- Vol. 6 (1), 1-8
- https://doi.org/10.1038/s41420-020-00373-0
Abstract
The development of the sequencing technologies allowed the generation of huge amounts of molecular data from a single cancer specimen, allowing the clinical oncology to enter the era of the precision medicine. This massive amount of data is highlighting new details on cancer pathogenesis but still relies on tissue biopsies, which are unable to capture the dynamic nature of cancer through its evolution. This assumption led to the exploration of non-tissue sources of tumoral material opening the field of liquid biopsies. Blood, together with body fluids such as urines, or stool, from cancer patients, are analyzed applying the techniques used for the generation of omics data. With blood, this approach would allow to take into account tumor heterogeneity (since the circulating components such as CTCs, ctDNA, or ECVs derive from each cancer clone) in a time dependent manner, resulting in a somehow “real-time” understanding of cancer evolution. Liquid biopsies are beginning nowdays to be applied in many cancer contexts and are at the basis of many clinical trials in oncology.Funding Information
- Associazione Italiana per la Ricerca sul Cancro (AIRC Start-Up ID 23219, IG#22206, IG#20473)
- Ministry of Health & MAECI Italy-China Science and Technology Cooperation
- Ministry of Health & MAECI Italy-China Science and Technology Cooperation
This publication has 93 references indexed in Scilit:
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingThe New England Journal of Medicine, 2012
- Preparing for Precision MedicineThe New England Journal of Medicine, 2012
- Stool DNA testing for the detection of pancreatic cancerCancer, 2011
- Molecular mechanisms of metastasis in breast cancer—clinical applicationsNature Reviews Clinical Oncology, 2010
- How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicineBritish Journal of Cancer, 2010
- Isoform-specific p73 knockout mice reveal a novel role for ΔNp73 in the DNA damage response pathwayJournal of Bone and Joint Surgery, 2010
- Influence of neuroblastoma stage on serum‐based detection of MYCN amplificationPediatric Blood & Cancer, 2009
- TAp73 knockout shows genomic instability with infertility and tumor suppressor functionsPublished by Cold Spring Harbor Laboratory ,2008
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Prediction of MYCN Amplification in Neuroblastoma Using Serum DNA and Real-Time Quantitative Polymerase Chain ReactionJournal of Clinical Oncology, 2005